| Barchart Demo Center |
$28.64
-0.28 (-0.97%)
as of May 17, 2024
as of May 17, 2024
| Last | 28.64 |
|---|---|
| Change | -0.28 (-0.97%) |
| Open | 28.90 |
| Prev. Close | 28.92 |
| Today's Range |
28.51
28.91
|
| 52wk Range |
25.20
40.37
|
| Volume | 26,066,791 |
| Avg Volume | 44,603,945 |
| Sector | SIC-2834 Pharmaceutical Preparations |
Perfomance Comparison
| Name | Today | 3-Month | 1-Year |
|---|---|---|---|
| PFE |
 -0.97% |
 +6.91% |
-22.07% |
| DJIA |
+0.34% |
 +3.13% |
+19.70% |
| S&P 500 |
+0.12% |
+2.83% |
+27.52% |
Key Statistics
| Annual EPS | -0.06 |
|---|---|
| Dividend Yield | 5.92% |
| P/E Ratio | 19.99 |
| Market Capitalization, $K | 160,817,891 |
| Weighted Alpha | -19.29 |
| Standard Deviation | -0.54 |
| Profit Margin | -0.56% |
| Beta | 0.63 |
Growth Rates
| YTD | -0.52% | |||
| 1-Year | -21.35% | |||
| 3-Year | -27.61% | |||
| 5-Year | -31.06% | |||
| 10-Year | -2.40% |
Opinion
| Sell | Hold | Buy |
Recent Headlines
Astellas Showcases Scientific Advancements Across its
PR Newswire - Mon May 13, 07:00AM CDT
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research from across its innovative portfolio of...(full story)
PFE: 28.64 (-0.28)
Pfizer Announces New Chief Strategy and Innovation
Business Wire - Mon May 06, 05:45AM CDT
Pfizer Inc. (NYSE: PFE) today announced that Andrew Baum, M.D., will join the company as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will be a member of Pfizer’s Executive Leadership Team report(full story)
PFE: 28.64 (-0.28)
Pfizer: Q1 Earnings Snapshot
AP - Wed May 01, 05:53AM CDT
Pfizer: Q1 Earnings Snapshot(full story)
PFE: 28.64 (-0.28)
Pfizer Reports First-Quarter 2024 Results
Business Wire - Wed May 01, 05:45AM CDT
Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2024 and raised its Adjusted (3) diluted EPS guidance while maintaining all other components of its 2024 financial guidance (6) .(full story)
PFE: 28.64 (-0.28)
Pfizer and Genmab Receive FDA Approval for Cervical
Baystreet - Tue Apr 30, 12:29PM CDT
In late April, Pfizer (NYSE:PFE) and Genmab received approval from the United States Food and Drug Administration ...(full story)
PFE: 28.64 (-0.28)